Glioblastoma, the brain cancer that Sen. John McCain has, is invariably — and accurately — described as aggressive and as having a poor prognosis: Not even Sen. Edward Kennedy or Beau Biden, with access to the best care and most cutting-edge therapies in the world, beat it. Recent advances, however, have persuaded some scientists that effective treatments are on the horizon — and some might even help McCain live longer than earlier patients did. 

“We’ve learned a tremendous amount about the biology of this cancer,” said Dr. David Reardon, director of neuro-oncology at Boston’s Dana-Farber Cancer Institute. That includes understanding “the mutations and other abnormalities that give tumors an advantage, how they adapt and become resistant [to chemotherapy], and how to get treatments across the blood-brain barrier” that is notorious for keeping out drugs.

As a result, he said, “there are an increasing number of drugs that are making their way toward the clinic.”


Market research company Informa Pharma Intelligence counts 87 experimental therapies, from vaccines and gene therapy to monoclonal antibodies (the workhorses of precision medicine), in clinical trials for glioblastoma. Most of those won’t be approved for years, if ever. But the newest tool in oncologists’ kit is one that McCain might benefit from immediately.

In June, the U.S. Food and Drug Administration approved an imaging agent that turns glioblastoma pink, making it stand out against healthy brain tissue. Normally, glioblastomas are so difficult to see that surgeons cannot “get it all” without also removing normal gray matter, which can leave patients with severe cognitive, speech, or other impairments.

Glioblastomas “have little tentacles growing into the normal brain that are challenging to see even with a microscope,” said Dr. Costas Hadjipanayis, chairman of neurosurgery at Mount Sinai Beth Israel in New York City. When a patient drinks the new agent, called Gleolan, three to five hours before surgery, it “allows us to visualize those fingers of tumor tissue,” he said.

Getting all of a tumor makes a big difference. In a 2016 analysis of 37 studies involving some 41,000 patients, researchers found that when surgeons removed all of a glioblastoma, patients were 38 percent less likely to die within the next year. They were only 16 percent less likely to die by the end of the second year, however, underlining how even “getting it all” is not the same as curing glioblastoma.

“Removing all the visible tumor does not cure this cancer — ever,” said Dr. Mark Gilbert of the National Cancer Institute. Years ago, surgeons removed the entire half of the brain that a glioblastoma was in. Even that “did not markedly increase survival,” he said: Patients still died because malignant cells had already invaded the rest of the brain.

Chemotherapy is of only limited use because glioblastomas shrug off the drugs like Iron Man swats away bullets. These tumors are a crazy quilt of different kinds of cells, said Gilbert. Each kind deploys different molecular tricks — a landmark paper identified four main types — in order to proliferate.

John McCain has been diagnosed with an aggressive form of brain cancer. Alex Hogan/STAT

A drug might shrink and contain the tumor for a few months, killing susceptible cells, but the surviving cells are resistant. “You knock out one of the pathways and the others go their merry way,” Gilbert said. “They say, fine, we have free rein,” multiplying and dividing unchecked. That’s why glioblastoma is so aggressive, with a high rate of recurrence and a five-year survival rate of barely 5 percent. Just half of patients are still alive 15 months after their diagnosis.

The exception is if a patient’s glioblastoma is much more uniform than the norm. In that case, it is “addicted” to one specific proliferation pathway that’s vulnerable to a molecularly targeted therapy, Gilbert said. Since McCain will have access to the best care, he will presumably have his tumor genetically profiled (which costs upward of $8,000) to see if it falls into this category. With any luck, he will be in the 2 percent to 3 percent of patients with an extremely uniform glioblastoma that succumbs to a therapy that knocks out its one proliferation pathway.

Otherwise, the only shot at a true cure is to kill the multiple types of cells that make up a glioblastoma, probably sequentially rather than simultaneously. “We recognize that one single approach will not cure glioblastoma,” said Ann Kingston of the National Brain Tumor Society.

But the biological version of whack-a-mole might. That would entail determining the molecular profile of the most abundant cells in the glioblastoma, killing those, then determining the profile of the survivors and going after those. One of the most promising experimental approaches to glioblastoma is therefore to enlist the immune system, which has an unmatched ability to seek out and destroy malignant cells that differ from one another in the way that glioblastoma cells do.

Last December, researchers at City of Hope hospital in Duarte, Calif., reported that they had gotten the much-publicized immunotherapy called CAR-T cells to attack one patient’s glioblastoma. CAR-Ts are immune cells that are removed from a patient and then genetically engineered to attack a particular molecule on tumor cells, and hence the tumors themselves. The 50-year-old patient had suffered a recurrence of glioblastoma after surgery, radiation, and the chemotherapy drug temozolomide. When he received multiple injections of CAR-Ts into his brain, his tumor regressed and was kept at bay for nearly eight months.

That suggested that “a better treatment may be attainable,” Christine Brown, who led the study, said at the time. “We can take a patient who has actively growing, advanced, metastatic multifocal glioblastoma, and we can see regression.”

In an indication of how initial hopes can be dashed, however, the man’s tumors returned in different parts of the brain “even more aggressively than before,” said a City of Hope spokeswoman. “In the end, we were unable to keep up with the rapid spread of his disease.” He died of glioblastoma in April.

That might be a warning sign of a big concern about CAR-Ts — they target a single molecule on tumor cells. Given the heterogeneity of glioblastoma cells, that might be way too few, said Dr. Donald O’Rourke of the Perelman School of Medicine at the University of Pennsylvania. Targeting a single molecule, he said, will almost certainly leave tumor cells that have different surface molecules untouched and unleashed.

Last week, O’Rourke and colleagues reported more sobering news about CAR-Ts and glioblastoma. CAR-Ts engineered to target a more common molecule than the City of Hope approach (it’s called EGFRvIII) penetrated glioblastomas in the Penn study’s 10 patients. But the tumors fought back. They created an “immunosuppressive microenvironment,” O’Rourke said, quashing the CAR-Ts.

NCI’s Gilbert, while “very excited” about approaches that target the EGFR molecule, estimated that only 5 percent to 40 percent of a glioblastoma’s cells sport that molecule on their surface.

“Even within the same tumor you have these different molecules,” O’Rourke said. “It’s kind of daunting and is going to be a problem.” He suspects, however, that if CAR-Ts are combined with existing immunotherapies, such as Yervoy and other so-called checkpoint inhibitors, they might be more effective. “But we have a lot of work to do,” he said.

Scientists hope that a different kind of immune therapy will hit more targets, and therefore more of the different kinds of cells in a glioblastoma, than CAR-Ts. Called a neoantigen vaccine, it consists of molecules (actually, pieces of them) found on the surface of glioblastoma cells. One patient’s surface molecules are different from other patients’, so neoantigen vaccines are the epitome of personalized therapy. The patient’s immune system recognizes the molecules as invaders and mounts an attack on the corresponding molecules on the tumor. The approach recently showed success in a small study of melanoma patients, and is being tested in glioblastoma patients in a clinical trial at Dana-Farber.

The hope is that a vaccine against one batch of molecules, and then another vaccine against the molecules that appear next, might keep pace with glioblastoma cells’ protean tendencies. But it takes weeks to make these individualized vaccines, time that patients might not have.

Even further along is a vaccine that also targets molecules on a patient’s unique glioblastoma but in a somewhat different way from the Dana-Farber approach. Manufacturer Northwest Biotherapeutics has recruited 331 glioblastoma patients into a late-stage clinical trial, and at this year’s meeting of the American Society of Clinical Oncology reported that 40 percent of patients treated with “DCVax-L” were still alive at 35 months, compared with 15 percent of patients receiving standard care; 24 percent of patients who got the vaccine were alive after four years, compared with 8 percent otherwise.

It’s a measure of how desperate the search for a glioblastoma cure is that one drug company has gone back to the original “war on cancer” launched by President Nixon 50 years ago to resurrect a compound that wasn’t fully investigated then (because of patent issues that are not longer an obstacle). It’s an old-line chemotherapy drug that damages cells’ DNA. Unfortunately, cells can often repair that damage, eventually making the drug ineffective.

DelMar Pharmaceuticals’s version attacks DNA at a place the repair machinery doesn’t reach, explained CEO Jeffrey Bacha. In a mid-stage clinical trial, patients whose glioblastoma had returned after surgery, radiation, and standard chemotherapy survived a median of 8.3 months, compared with about three months in the comparison group.

Leave a Comment

Please enter your name.
Please enter a comment.

  • My dad is about the same age and had a second surgery to remove the tumor. He had excellent improvement in his ability to speak and overall felt/seemed much more normal. This was after it grew back after a first surgery and temodar and radiation.

  • My mom who is 63 was diagnosed in April 2018 with grade IV GBM. She has completed her 6 weeks radiation as well as 5 rounds of temodar. She NOW has the option (since swelling and tumor size have dramatically reduced) to have the tumor removed. Has ANYONE or does anyone know of anything stating that removing the tumor at this point has any benefit? I know getting it out is of course best. But stopping her Avastin treatment as well as skipping a month of chemo is needed for Duke University to remove her tumor. Is it worth it to remove tumor after start of treatments? I am desperate of answers to this question. I have googled it endlessly with nothing found. Thank you

  • If you are searching for other options for treatment of GBM’s, there are numerous groups on Facebook who re-post on-line articles about new, cutting-edge from medical journals from all over the world. Do searches for: long term survivors; GBM caretakers/spouses; guides to surviving GBM’s; glioblastoma survival; brain cancer, etc. Good luck.

  • The article ignores the game changing advances in fighting this disease and fails to give readers an accurate picture of current cutting-edge technology. GBM patients and their families need know about DNA analysis of tumors that help taylor treatments to that patient and increase survivability.

    My husband has survived 5.7 years with this cancer. A vast majority of patients die within 6 months of diagnosis while some will survive 14 months. Current survival rates for 2 years has increased to 10% because of this new treatments/technologies.

    In Dec. 2012, my husband had a total gross resection (removing all parts of the visible tumor) of a glioblastoma multiforme (GBM) Stage IV brain tumor measuring 2.5 cm. Our surgeon at MD Anderson in Houston, TX, called it small. It was the size of a walnut and located in the left temporal lobe. It was followed by 6 weeks of radiation and 6 months of Temodar (chemo). 4 yrs. 11 months later, a new lesion appeared in the hippocampus and amygdala, and he was treated with Avastin (an infusion), gleostine (a chemo), and we added cannabinoids (THC & CBD oils) to help with the side effects, seizures and fight GBM glial cancer cells. (Normal survival rate of a recurrent GBM is 3.5 to 4.5 months.)

    By April 23, 2018, those enhancements were completely gone but the new MRI at MD Anderson showed that a suspicious area had transformed into a new active GBM measuring .8 cm. He finished another round of Avastin on June 28th and will finish his radiation on July 3, 2018.

    What’s the difference?

    Why is he surviving so long?

    How could he beat GBM twice and be on track to beat it a 3rd time?

    DNA analysis of his tumor showed that he had an MGM methylated mutation (62% highly methylated) that is a genetic marker for long term survivability. Translation: the mutation sets up a perfect storm where cancer treatments kill/subdue GBM glial cells. The surgery, temodar, radiation (twice), gleostine and avastin all worked to get rid of his visible enhancements.

    When the GBM comes back a 4th time (and it will, it always comes back), Phase III trials of Immunotherapies using the cold virus & the patients own stem cells (MD Anderson); poliovirus (Duke University) and others utilizing HIV, oncolytic virus, virotherapy, herpes simplex, adenovirus, measles, Newcastle disease virus, reovirus, vesicular stomatitis virus, parvovirus, vaccinia virus, myxoma virus, and others will be available as Phase III clinical trials or approved by the FDA.

    Sharon Begley neglected to mention these new approaches to helping patients survive GBM. She did a good job of taking medical jargon and translating it into everyday English. Her analysis of technologies that we were not aware of was valuable and eye-opening. But ignoring the DNA analysis of GBM’s and its effect on research to enhance long-term survivability, is an oversite.

    People reading this article are searching for answers to a deadly and fast growing cancer that is engulfed in so much technical jargon, that it is hard to make the right choice for treatment. Making the right decision for yourself or your loved one is just as important as actually taking the treatment.

    • My dear Lady thank you for the information you posted my Son was diagnosed last October with glioblastoma he had surgery radiation and chemo temedore but last week and MRI show a regrow and he is having surgery again tomorrow morning I am so worry after they plan on targeted treatment with 3 diferent drugs one of them is Opdivo but I’m not sure that’s the way I believe there are better options I have been some research my self but its so hard there’s so much information it’s confusing at times I like what you and your Husband are doing and will show my Son your post if you know anything more on this terrible decease please let me know I don’t want to loose my Baby . Thank you again

    • Cel, I am so sorry to hear that your child is battling this disease.

      And yes, the medical jargon is overwhelming for this GBM brain cancer. Paul and I have been studying and reading about this disease for almost six years now (if you count the time prior to the surgery at MD Anderson (Houston, TX). He is a physicist and I’m a tech writer so we have researched 100’s of articles about GBM.

      You are absolutely correct. It is so hard to know what to research because it seems like each GBM is unique with it’s own set of problems. So not all articles you find on the web are relevant to your GBM.

      Look on Facebook. There are groups there that post constantly about current research on GBM. You can find a site that you like and ask basic questions. You’ll get answers right away from most of them. Good luck.

    • Another huge is the location. Procedures like the polio trial require access to the tumor. Sadly not an option for us. Leads to any promising trials that dont involve surgical access would be greatly appreciated.

    • Hi Quicksilver,
      I know these posts are months old, but I am hoping you see my question. I am trying to save my Mom. Can you tell me the dosing of CBD/THC that you were giving and the frequency a day? Where you using any other supplements or doing absolutely anything besides the medical treatment, even if it is dietary, please share. Also, can you give me the name of a trusted Dr at MD Anderson? Thanks

  • Respected madam,
    My name is Dilip from india, my father is suffering from gliblastoma grade 4 from Jan 2014. Now in December 2017 he had 2nd surgery -followed by radiation and chemo therapy. Now may 2018 he has bit dipleted & feeling hard to walk .

    Can you please suggest – what can we do best from our side, what are available treatment for further?
    Please suggest me madam.

    Thank you
    Yours faithfully

    • If you are searching for other options for treatment of GBM’s, there are numerous groups on Facebook who re-post on-line articles about new, cutting-edge from medical journals from all over the world. Do searches for: long term survivors; GBM caretakers/spouses; guides to surviving GBM’s; glioblastoma survival; brain cancer, etc. Good luck.

    • I searched many sites & posts on face book too, Recently i got to knew about new invasive way for treatment of GBH-Grade 4 type by: SPMF treatment (@ sbf health care) i.e sequentially programmed magnetic field therapy.
      Please, Can any one suggest about this treatment usefulness, whether will it be useful -how trust worthy will it be.

    • Yes, if you use those treatments and ignore the explosion of new approaches and treatments designed to kick GBM’s to the curb.

  • Hi, my mom just had and MRI done on Wednesday they said it looks to be glioblastoma… I’m scared and worried because we are waiting to see a neurosurgeon and oncologist I need help and answers..

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy